Overview:

Summary

The industry analysis specialist’s new report, “Irritable Bowel Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global irritable bowel syndrome market. The report identifies the key trends shaping and driving the global irritable bowel syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global irritable bowel syndrome sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key driver and challenges of the global irritable bowel syndrome market. Its scope includes:

• Annualized global irritable bowel syndrome market revenues data from 2000 to 2009, forecast for seven years to 2016.

• Key geographies covered in this report include the US, the UK, Italy, Spain, Germany, France and Japan.

• Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include guanylate cyclase type C receptor agonists, serotonin receptors targets, corticotrophin releasing factor 1 receptor antagonists, NK receptor targets and 5-aminosalicylate targets.

• Analysis of the current and future market competition in the global irritable bowel syndrome market. Key market players covered include Sucampo Pharmaceuticals, Tillotts Pharma AG, GSK, Axcan Pharma, Salix Pharmaceuticals and Tioga Pharmaceuticals.

• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

• Key topics covered include a strategic competitor assessment, market characterization, unmet needs and implications for the future irritable bowel syndrome market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the global irritable bowel syndrome market.

• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global irritable bowel syndrome market in future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

• What’s the next big thing in the global irritable bowel syndrome market landscape? - Identify, understand and capitalize.

Companies Mentioned

Ironwood pharmaceuticals and Forest laboratories
Tioga Pharmaceuticals
Alimentary Health Ltd & P & G
Lexicon
Salix Pharmaceuticals
Astellas Pharma